Understanding quality of life in patients with intracranial germ cell tumors
Prospective Study on Quality of Life in Patients With Intracranial Germ Cell Tumors
This study looks at how living with intracranial germ cell tumors affects the quality of life for patients to help improve their care and treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 150 (estimated) |
| Ages | 3 Years to 30 Years |
| Sex | All |
| Sponsor | Beijing Tiantan Hospital Academic / other |
| Locations | 1 site (Beijing) |
| Trial ID | NCT05124964 on ClinicalTrials.gov |
What this trial studies
This observational study aims to characterize the quality of life in patients diagnosed with intracranial germ cell tumors, a rare condition. By utilizing validated assessment tools such as the PedsQL 4.0 Scale and Short Form-36, the study seeks to gather prospective data on how current treatment strategies impact survivors' quality of life. Given that over 90% of patients with germinoma survive for at least ten years, understanding their long-term quality of life is crucial for optimizing treatment approaches. The findings will help inform better care strategies for these patients.
Who should consider this trial
Good fit: Ideal candidates for this study are patients aged 3 to 21 years who have been newly diagnosed with primary intracranial germ cell tumors.
Not a fit: Patients with relapsed disease or those who demonstrate poor compliance may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment strategies that enhance the quality of life for survivors of intracranial germ cell tumors.
How similar studies have performed: While there have been limited retrospective studies on this topic, this prospective approach is novel and aims to fill a significant gap in understanding quality of life for this patient population.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 3 years ≤ age ≤ 21 years * Newly diagnosed primary intracranial germ cell tumors * Written informed consent Exclusion Criteria: * Relapsed disease * Poor compliance
Where this trial is running
Beijing
- Beijing Tiantan Hospital — Beijing, China (Recruiting)
Study contacts
- Principal investigator: Tao Jiang, MD, PhD — Beijing Tiantan Hospital
- Study coordinator: Bo Li, MD, PhD
- Email: libo@bjtth.org
- Phone: (86)10-59975581
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.